RBC Capital Sticks to Their Buy Rating for Exelixis (EXEL)
A Quick Look at Today's Ratings for Exelixis(EXEL.US), With a Forecast Between $29 to $38
Exelixis Price Target Raised to $36.00/Share From $32.00 by Wells Fargo
Exelixis Is Maintained at Outperform by BMO Capital
Exelixis Analyst Ratings
A Quick Look at Today's Ratings for Exelixis(EXEL.US), With a Forecast Between $29 to $38
Exelixis Analyst Ratings
TD Cowen Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $34
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Korro Bio (KRRO) and Vertex Pharmaceuticals (VRTX)
A Quick Look at Today's Ratings for Exelixis(EXEL.US), With a Forecast Between $30 to $34
A Quick Look at Today's Ratings for Exelixis(EXEL.US), With a Forecast Between $27 to $34
Morgan Stanley Lifts Price Target on Exelixis to $30 From $28, Keeps Equalweight Rating
Exelixis Is Maintained at Market Outperform by JMP Securities
Goldman Sachs Remains a Sell on Exelixis (EXEL)
Exelixis Hold Rating: Navigating Legal Wins and Strategic Acquisitions Amid Uncertain Revenue Transition
Exelixis Analyst Ratings
Citi Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $31
Truist Financial Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $33
Truist Financial Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $33
Exelixis Analyst Ratings